Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Waldenstrom Macroglobulinemia | 118 | 2024 | 1073 | 11.950 |
Why?
|
Myeloid Differentiation Factor 88 | 47 | 2024 | 587 | 6.560 |
Why?
|
Receptors, CXCR4 | 28 | 2021 | 727 | 3.160 |
Why?
|
Adenine | 29 | 2024 | 987 | 2.570 |
Why?
|
Piperidines | 29 | 2024 | 1656 | 2.010 |
Why?
|
Pyrazoles | 22 | 2024 | 2009 | 1.780 |
Why?
|
Pyrimidines | 22 | 2024 | 3028 | 1.570 |
Why?
|
Immunoglobulin M | 27 | 2021 | 1527 | 1.360 |
Why?
|
Mutation | 40 | 2024 | 30052 | 1.230 |
Why?
|
Chromosome Deletion | 2 | 2020 | 1386 | 0.920 |
Why?
|
Chromosomes, Human, Pair 6 | 2 | 2020 | 367 | 0.730 |
Why?
|
Lymphoma, B-Cell | 4 | 2022 | 940 | 0.640 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2020 | 452 | 0.610 |
Why?
|
Proto-Oncogene Proteins c-hck | 5 | 2022 | 46 | 0.590 |
Why?
|
Chemokine CXCL13 | 1 | 2017 | 59 | 0.580 |
Why?
|
Protein Kinase Inhibitors | 8 | 2021 | 5671 | 0.500 |
Why?
|
Signal Transduction | 18 | 2020 | 23445 | 0.500 |
Why?
|
B-Lymphocytes | 13 | 2022 | 4758 | 0.470 |
Why?
|
Point Mutation | 3 | 2021 | 1595 | 0.460 |
Why?
|
Warts | 1 | 2013 | 66 | 0.440 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2021 | 5305 | 0.440 |
Why?
|
Boronic Acids | 6 | 2012 | 915 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11742 | 0.400 |
Why?
|
Genomics | 4 | 2020 | 5821 | 0.400 |
Why?
|
Pyrazines | 6 | 2012 | 1201 | 0.380 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13639 | 0.360 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2013 | 547 | 0.340 |
Why?
|
Bone Marrow | 10 | 2021 | 2911 | 0.340 |
Why?
|
Blood Viscosity | 5 | 2019 | 124 | 0.320 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2013 | 369 | 0.310 |
Why?
|
Agammaglobulinemia | 1 | 2009 | 171 | 0.300 |
Why?
|
Humans | 128 | 2024 | 761504 | 0.280 |
Why?
|
NF-kappa B | 6 | 2020 | 2490 | 0.270 |
Why?
|
Sulfonamides | 3 | 2024 | 1978 | 0.270 |
Why?
|
Immunoglobulin A | 1 | 2009 | 978 | 0.260 |
Why?
|
Gene Deletion | 1 | 2013 | 2665 | 0.260 |
Why?
|
Neoplasm Proteins | 5 | 2019 | 3617 | 0.260 |
Why?
|
Apoptosis | 11 | 2020 | 9486 | 0.240 |
Why?
|
Aged | 54 | 2024 | 169289 | 0.240 |
Why?
|
Aged, 80 and over | 32 | 2021 | 58976 | 0.240 |
Why?
|
Sp1 Transcription Factor | 2 | 2016 | 140 | 0.230 |
Why?
|
Iron | 1 | 2013 | 1793 | 0.230 |
Why?
|
Middle Aged | 62 | 2021 | 220895 | 0.230 |
Why?
|
Quinazolinones | 2 | 2016 | 221 | 0.230 |
Why?
|
Plasma Cells | 5 | 2022 | 599 | 0.220 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2019 | 2825 | 0.220 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2023 | 2510 | 0.220 |
Why?
|
Receptors, IgE | 1 | 2005 | 375 | 0.220 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 10 | 2014 | 694 | 0.220 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 3 | 2015 | 179 | 0.210 |
Why?
|
Amino Acid Substitution | 5 | 2019 | 1738 | 0.210 |
Why?
|
Purines | 3 | 2016 | 607 | 0.210 |
Why?
|
Receptors, IgG | 4 | 2011 | 559 | 0.200 |
Why?
|
Neprilysin | 1 | 2005 | 478 | 0.200 |
Why?
|
Treatment Outcome | 24 | 2024 | 64680 | 0.200 |
Why?
|
Survival Rate | 11 | 2021 | 12725 | 0.190 |
Why?
|
Male | 61 | 2024 | 360804 | 0.190 |
Why?
|
Disease-Free Survival | 10 | 2019 | 6814 | 0.190 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 615 | 0.190 |
Why?
|
Antibodies, Monoclonal | 11 | 2020 | 9177 | 0.190 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2017 | 2425 | 0.170 |
Why?
|
Lymphoproliferative Disorders | 2 | 2014 | 531 | 0.170 |
Why?
|
Phospholipase C gamma | 1 | 2020 | 131 | 0.170 |
Why?
|
Prognosis | 12 | 2024 | 29625 | 0.170 |
Why?
|
Female | 57 | 2024 | 392644 | 0.170 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2020 | 1405 | 0.170 |
Why?
|
Immunoglobulin G | 3 | 2014 | 4544 | 0.170 |
Why?
|
Paraproteinemias | 2 | 2012 | 248 | 0.160 |
Why?
|
Multiple Myeloma | 4 | 2021 | 5146 | 0.160 |
Why?
|
Nucleosides | 2 | 2009 | 131 | 0.150 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 83 | 0.150 |
Why?
|
p21-Activated Kinases | 1 | 2018 | 128 | 0.150 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2018 | 8547 | 0.150 |
Why?
|
Antibodies, Neoplasm | 2 | 2011 | 281 | 0.140 |
Why?
|
Neoplasms, Second Primary | 2 | 2015 | 1052 | 0.140 |
Why?
|
Plasma | 1 | 2020 | 586 | 0.140 |
Why?
|
Adult | 37 | 2021 | 221177 | 0.140 |
Why?
|
Lymphoma, Non-Hodgkin | 4 | 2015 | 1374 | 0.140 |
Why?
|
Acrylamides | 1 | 2018 | 260 | 0.140 |
Why?
|
Paracrine Communication | 1 | 2018 | 277 | 0.130 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2011 | 774 | 0.130 |
Why?
|
DNA Methylation | 3 | 2020 | 4398 | 0.130 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 106 | 0.130 |
Why?
|
Cyclophilin A | 1 | 2015 | 58 | 0.120 |
Why?
|
SEER Program | 3 | 2015 | 1450 | 0.120 |
Why?
|
Cell Proliferation | 7 | 2018 | 10445 | 0.120 |
Why?
|
Cell Survival | 8 | 2018 | 5791 | 0.120 |
Why?
|
Cytokines | 3 | 2018 | 7396 | 0.120 |
Why?
|
Aminopyridines | 1 | 2018 | 573 | 0.120 |
Why?
|
Epigenomics | 1 | 2020 | 943 | 0.120 |
Why?
|
Gene Expression Profiling | 5 | 2016 | 9420 | 0.120 |
Why?
|
von Willebrand Factor | 1 | 2018 | 673 | 0.110 |
Why?
|
Drug Tolerance | 1 | 2015 | 367 | 0.110 |
Why?
|
Vidarabine | 2 | 2012 | 336 | 0.110 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 2020 | 0.110 |
Why?
|
Survival Analysis | 8 | 2020 | 10090 | 0.110 |
Why?
|
Antigens, CD | 3 | 2011 | 4003 | 0.110 |
Why?
|
Codon, Nonsense | 1 | 2014 | 285 | 0.110 |
Why?
|
Thalidomide | 2 | 2009 | 885 | 0.110 |
Why?
|
Translocation, Genetic | 2 | 2021 | 1393 | 0.110 |
Why?
|
Gene Expression | 6 | 2019 | 7581 | 0.110 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2016 | 545 | 0.100 |
Why?
|
Frameshift Mutation | 1 | 2014 | 392 | 0.100 |
Why?
|
Cell Line, Tumor | 10 | 2021 | 16981 | 0.100 |
Why?
|
Disease Progression | 6 | 2021 | 13506 | 0.100 |
Why?
|
Comparative Genomic Hybridization | 1 | 2013 | 473 | 0.100 |
Why?
|
Lymphoma | 1 | 2021 | 1901 | 0.100 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2735 | 0.100 |
Why?
|
Transferrin | 1 | 2013 | 283 | 0.100 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2012 | 85 | 0.100 |
Why?
|
Mice, SCID | 5 | 2021 | 2626 | 0.100 |
Why?
|
Hydroxamic Acids | 2 | 2011 | 481 | 0.100 |
Why?
|
Transcriptional Activation | 2 | 2016 | 1756 | 0.100 |
Why?
|
Polymerase Chain Reaction | 4 | 2015 | 6075 | 0.090 |
Why?
|
Molecular Targeted Therapy | 3 | 2017 | 2811 | 0.090 |
Why?
|
Glycoproteins | 2 | 2011 | 2203 | 0.090 |
Why?
|
Matrix Metalloproteinase 8 | 1 | 2011 | 56 | 0.090 |
Why?
|
Alleles | 3 | 2019 | 6863 | 0.090 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39106 | 0.090 |
Why?
|
Cyclophosphamide | 3 | 2012 | 2218 | 0.090 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 1993 | 0.090 |
Why?
|
Bone Marrow Cells | 3 | 2011 | 2416 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1486 | 0.090 |
Why?
|
Mast Cells | 3 | 2008 | 1392 | 0.090 |
Why?
|
Cell Communication | 1 | 2018 | 1657 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 5 | 2020 | 6484 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.090 |
Why?
|
Anemia | 2 | 2011 | 1509 | 0.090 |
Why?
|
Ubiquitins | 1 | 2012 | 366 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1027 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3639 | 0.080 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2015 | 1135 | 0.080 |
Why?
|
DNA Repair | 1 | 2018 | 2045 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2019 | 1870 | 0.080 |
Why?
|
Antigens, CD20 | 2 | 2007 | 200 | 0.080 |
Why?
|
Tunicamycin | 1 | 2008 | 108 | 0.080 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2011 | 353 | 0.080 |
Why?
|
Mutation, Missense | 1 | 2018 | 2571 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2014 | 710 | 0.080 |
Why?
|
Lymphocytes | 2 | 2013 | 2612 | 0.080 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 687 | 0.080 |
Why?
|
Promoter Regions, Genetic | 2 | 2016 | 5789 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2917 | 0.070 |
Why?
|
Genes, Regulator | 1 | 2009 | 373 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2016 | 916 | 0.070 |
Why?
|
Boron Compounds | 2 | 2020 | 182 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2455 | 0.070 |
Why?
|
Sequence Analysis, DNA | 3 | 2015 | 4740 | 0.070 |
Why?
|
Gene Regulatory Networks | 1 | 2016 | 1745 | 0.070 |
Why?
|
Hepatitis C Antibodies | 1 | 2007 | 146 | 0.070 |
Why?
|
Family Health | 1 | 2011 | 1257 | 0.070 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9606 | 0.070 |
Why?
|
Stress, Physiological | 2 | 2011 | 1403 | 0.070 |
Why?
|
Flow Cytometry | 5 | 2013 | 5869 | 0.070 |
Why?
|
Dexamethasone | 3 | 2020 | 1948 | 0.070 |
Why?
|
Transcription Factors | 3 | 2015 | 12128 | 0.070 |
Why?
|
Membrane Proteins | 2 | 2015 | 7856 | 0.060 |
Why?
|
Glycine | 2 | 2020 | 663 | 0.060 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 303 | 0.060 |
Why?
|
Simvastatin | 1 | 2008 | 346 | 0.060 |
Why?
|
Blood Proteins | 1 | 2011 | 1173 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2091 | 0.060 |
Why?
|
Chromosome Mapping | 1 | 2013 | 4615 | 0.060 |
Why?
|
Interleukin-1 Receptor-Associated Kinases | 2 | 2017 | 76 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2022 | 2898 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3802 | 0.060 |
Why?
|
DNA Mutational Analysis | 3 | 2021 | 4111 | 0.060 |
Why?
|
Biopsy | 3 | 2019 | 6766 | 0.060 |
Why?
|
CD40 Ligand | 1 | 2006 | 522 | 0.060 |
Why?
|
Prospective Studies | 8 | 2021 | 54425 | 0.060 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17635 | 0.060 |
Why?
|
Mastocytosis | 1 | 2006 | 150 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2007 | 754 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2021 | 6132 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2005 | 263 | 0.050 |
Why?
|
Mice, Inbred NOD | 2 | 2021 | 1827 | 0.050 |
Why?
|
Polymorphism, Genetic | 3 | 2011 | 4243 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 1405 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2223 | 0.050 |
Why?
|
Endoplasmic Reticulum | 1 | 2008 | 1134 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4511 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13446 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 5 | 2019 | 17904 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12974 | 0.050 |
Why?
|
Protein Multimerization | 2 | 2017 | 983 | 0.050 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2008 | 1349 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2007 | 2341 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 15936 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6567 | 0.050 |
Why?
|
Retinal Vessels | 1 | 2006 | 852 | 0.050 |
Why?
|
Retinal Diseases | 1 | 2006 | 705 | 0.040 |
Why?
|
Vasodilator Agents | 1 | 2004 | 973 | 0.040 |
Why?
|
Retrospective Studies | 10 | 2020 | 80636 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2011 | 3712 | 0.040 |
Why?
|
Incidence | 6 | 2016 | 21353 | 0.040 |
Why?
|
Paraproteins | 1 | 2020 | 38 | 0.040 |
Why?
|
MicroRNAs | 1 | 2016 | 3816 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2022 | 535 | 0.040 |
Why?
|
Hepacivirus | 1 | 2007 | 1336 | 0.040 |
Why?
|
Antigens, CD19 | 2 | 2014 | 424 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2015 | 3602 | 0.040 |
Why?
|
Genome, Human | 1 | 2012 | 4425 | 0.040 |
Why?
|
Animals | 12 | 2021 | 168459 | 0.040 |
Why?
|
Databases, Factual | 1 | 2014 | 7967 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2019 | 9539 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 2385 | 0.040 |
Why?
|
Genotype | 4 | 2017 | 12990 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2020 | 329 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2013 | 5796 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12463 | 0.040 |
Why?
|
Germinal Center | 1 | 2021 | 380 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2008 | 1394 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8224 | 0.040 |
Why?
|
Case-Control Studies | 5 | 2020 | 22176 | 0.040 |
Why?
|
Hemoglobins | 2 | 2015 | 1525 | 0.040 |
Why?
|
Models, Biological | 1 | 2014 | 9469 | 0.040 |
Why?
|
RNA, Viral | 1 | 2007 | 2846 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18252 | 0.040 |
Why?
|
Phosphorylation | 3 | 2016 | 8320 | 0.040 |
Why?
|
Mice | 8 | 2021 | 81525 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2007 | 1589 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2018 | 189 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2007 | 2200 | 0.040 |
Why?
|
Protein Binding | 3 | 2017 | 9351 | 0.040 |
Why?
|
Drug Synergism | 2 | 2015 | 1755 | 0.040 |
Why?
|
Cell Line | 2 | 2011 | 15601 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2011 | 4853 | 0.040 |
Why?
|
Hematocrit | 2 | 2011 | 623 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2014 | 3597 | 0.030 |
Why?
|
Pathology, Molecular | 1 | 2020 | 328 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4575 | 0.030 |
Why?
|
Plasmapheresis | 1 | 2017 | 206 | 0.030 |
Why?
|
Immunoblotting | 2 | 2011 | 1646 | 0.030 |
Why?
|
Hepatitis C | 1 | 2007 | 1584 | 0.030 |
Why?
|
Histone Deacetylases | 2 | 2011 | 719 | 0.030 |
Why?
|
Cohort Studies | 3 | 2015 | 41487 | 0.030 |
Why?
|
von Willebrand Diseases | 1 | 2018 | 132 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2009 | 3613 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5821 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6935 | 0.030 |
Why?
|
Histocytochemistry | 1 | 2016 | 698 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2020 | 8002 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3810 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2016 | 523 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2016 | 544 | 0.030 |
Why?
|
Octamer Transcription Factor-2 | 1 | 2014 | 7 | 0.030 |
Why?
|
Vincristine | 2 | 2009 | 1036 | 0.030 |
Why?
|
Blotting, Western | 2 | 2013 | 5035 | 0.030 |
Why?
|
Inhibitor of Differentiation Protein 2 | 1 | 2014 | 30 | 0.030 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 178 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2016 | 491 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 678 | 0.030 |
Why?
|
Piperazines | 1 | 2004 | 2523 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2024 | 2244 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 452 | 0.030 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 589 | 0.030 |
Why?
|
Cells, Cultured | 4 | 2013 | 18965 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 612 | 0.030 |
Why?
|
Caspase 3 | 1 | 2016 | 731 | 0.030 |
Why?
|
Drug Resistance | 1 | 2019 | 1596 | 0.030 |
Why?
|
Base Sequence | 2 | 2016 | 12441 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3245 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2014 | 454 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11118 | 0.030 |
Why?
|
Clone Cells | 1 | 2016 | 1659 | 0.030 |
Why?
|
Prednisone | 2 | 2009 | 1563 | 0.030 |
Why?
|
Neoplasms | 2 | 2011 | 22170 | 0.030 |
Why?
|
Stem Cells | 1 | 2005 | 3522 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2016 | 1529 | 0.020 |
Why?
|
Neutropenia | 2 | 2009 | 885 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 714 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3305 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
Leucine | 1 | 2013 | 548 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2014 | 855 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2018 | 1264 | 0.020 |
Why?
|
Proline | 1 | 2013 | 457 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2013 | 878 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13380 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 3076 | 0.020 |
Why?
|
Lentivirus | 1 | 2013 | 508 | 0.020 |
Why?
|
Doxorubicin | 2 | 2009 | 2224 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2011 | 397 | 0.020 |
Why?
|
Age Factors | 2 | 2018 | 18395 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2016 | 0.020 |
Why?
|
Risk Factors | 3 | 2017 | 74206 | 0.020 |
Why?
|
beta Catenin | 1 | 2015 | 1040 | 0.020 |
Why?
|
Drug Evaluation | 1 | 2011 | 641 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 871 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3877 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1612 | 0.020 |
Why?
|
Gene Silencing | 1 | 2016 | 1509 | 0.020 |
Why?
|
Chlorambucil | 1 | 2008 | 42 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1886 | 0.020 |
Why?
|
Cladribine | 1 | 2008 | 34 | 0.020 |
Why?
|
Electrophoresis, Capillary | 1 | 2009 | 63 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2018 | 6216 | 0.020 |
Why?
|
Plasmids | 1 | 2014 | 2269 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2011 | 1060 | 0.020 |
Why?
|
Time Factors | 3 | 2021 | 39967 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2015 | 1118 | 0.020 |
Why?
|
Oligopeptides | 1 | 2014 | 1187 | 0.020 |
Why?
|
United States | 4 | 2021 | 72334 | 0.020 |
Why?
|
Cell Death | 1 | 2014 | 1678 | 0.020 |
Why?
|
DNA Damage | 1 | 2018 | 2446 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2919 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4278 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2396 | 0.020 |
Why?
|
Immunotherapy | 2 | 2016 | 4652 | 0.020 |
Why?
|
Drug Discovery | 1 | 2016 | 1051 | 0.020 |
Why?
|
Caspases | 1 | 2011 | 879 | 0.020 |
Why?
|
Immunoglobulins | 1 | 2011 | 853 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2865 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 21012 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 10766 | 0.020 |
Why?
|
Phosphorylcholine | 1 | 2008 | 153 | 0.020 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2011 | 632 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2831 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 1006 | 0.020 |
Why?
|
Binding Sites | 1 | 2016 | 6055 | 0.020 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2006 | 239 | 0.020 |
Why?
|
Ophthalmoscopy | 1 | 2006 | 171 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2016 | 3208 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11076 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 5439 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2016 | 3702 | 0.020 |
Why?
|
Interphase | 1 | 2005 | 228 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13255 | 0.020 |
Why?
|
Protein Folding | 1 | 2008 | 870 | 0.010 |
Why?
|
Trans-Activators | 1 | 2014 | 2856 | 0.010 |
Why?
|
Models, Genetic | 1 | 2014 | 3442 | 0.010 |
Why?
|
Cell Differentiation | 2 | 2014 | 11528 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 3429 | 0.010 |
Why?
|
Heterozygote | 1 | 2011 | 2787 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2011 | 2707 | 0.010 |
Why?
|
Karyotyping | 1 | 2005 | 1171 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2016 | 5112 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2850 | 0.010 |
Why?
|
Cell Movement | 1 | 2015 | 5203 | 0.010 |
Why?
|
Pedigree | 1 | 2011 | 4542 | 0.010 |
Why?
|
Transfection | 1 | 2011 | 5774 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2006 | 1371 | 0.010 |
Why?
|
Cell Cycle | 1 | 2011 | 2932 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2006 | 1341 | 0.010 |
Why?
|
Sulfones | 1 | 2004 | 448 | 0.010 |
Why?
|
Tumor Burden | 1 | 2008 | 1893 | 0.010 |
Why?
|
Health Surveys | 1 | 2011 | 4061 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10552 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 11903 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 2009 | 1181 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12795 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3201 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11121 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2018 | 9280 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8830 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3734 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2008 | 2827 | 0.010 |
Why?
|
Graft Survival | 1 | 2007 | 3819 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 59243 | 0.010 |
Why?
|
Recurrence | 1 | 2007 | 8465 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7594 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20570 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 36426 | 0.000 |
Why?
|